Article
Rheumatology
Yvette Meissner, Martin Schaefer, Katinka Albrecht, Joern Kekow, Silke Zinke, Hans-Peter Tony, Anja Strangfeld
Summary: In this German observational cohort study, the occurrence rate of MACE was not higher with JAKi compared to other DMARDs. However, individual JAKis showed different unadjusted incident rates.
Article
Rheumatology
Gulsen Ozen, Sofia Pedro, Kaleb Michaud
Summary: A study comparing opioids and NSAIDs in patients with rheumatoid arthritis found that opioids had similar MACE risk but higher rates of all-cause mortality and VTE, suggesting that opioids are not safer than NSAIDs.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Cynthia S. Crowson, Tina M. Gunderson, Hayley J. Dykhoff, Elena Myasoedova, Elizabeth J. Atkinson, Vanessa L. Kronzer, Caitrin M. Coffey, John M. Davis
Summary: This study comprehensively assessed the burden of multimorbidity in patients with rheumatoid arthritis (RA) and found that RA patients have a higher prevalence of multimorbidity compared to non-RA patients. Interstitial lung disease, fibromyalgia, osteoarthritis, and osteoporosis were common morbidities in RA patients.
Article
Rheumatology
Johanna M. Maassen, Sytske Anne Bergstra, Arvind Chopra, Nimmisha Govind, Elizabeth A. Murphy, David Vega-Morales, Tom W. J. Huizinga, Cornelia F. Allaart
Summary: This study found that RA patients onset above 65 years old include more men and seronegative arthritis, and were initially treated slightly differently than younger patients. However, there were no clinically relevant differences in timing of a next treatment step or response to treatment between different age groups.
Article
Medicine, General & Internal
Seonyoung Kang, Kyungdo Han, Jin-Hyung Jung, Yeonghee Eun, In Young Kim, Jiwon Hwang, Eun-Mi Koh, Seulkee Lee, Hoon-Suk Cha, Hyungjin Kim, Jaejoon Lee
Summary: This large-scale nationwide cohort study investigated the association between cardiovascular disease (CVD) risk and rheumatoid arthritis (RA) and factors that may increase CVD risk. The study found that RA patients had a 50% higher risk of myocardial infarction (MI) and a 20% higher risk of stroke. The association between RA and CVD was more prominent in females, and the association between RA and MI risk was significant in individuals without diabetes.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
Viktor Molander, Hannah Bower, Thomas Frisell, Benedicte Delcoigne, Daniela Di Giuseppe, Johan Askling
Summary: Patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi) have a higher incidence of venous thromboembolism (VTE) compared to those treated with other biological disease modifying antirheumatic drugs (bDMARDs), especially in terms of pulmonary embolism (PE).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Gulsen Ozen, Sofia Pedro, Rebecca Schumacher, Teresa Simon, Kaleb Michaud
Summary: In patients with rheumatoid arthritis, factors such as older age, male sex, comorbidities, prior fracture, worse disability, higher disease activity, and glucocorticoid use increase the risk of both venous thromboembolism (VTE) and atherosclerotic cardiovascular disease (ASCVD). Traditional cardiovascular disease risk factors are common to both ASCVD and VTE, with obesity being an exception that only increases the risk of ASCVD. The study also found that the risk of ASCVD doubles after an unprovoked VTE, suggesting that VTE may be part of a spectrum of pan-cardiovascular syndrome mediated by inflammation in rheumatoid arthritis.
Article
Medicine, General & Internal
Benedicte Delcoigne, Sella A. Provan, Eirik K. Kristianslund, Johan Askling, Lotta Ljung
Summary: This study aimed to estimate the short-term risks of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) based on their current disease activity, including remission. The results showed that failure to reach remission is associated with an increased risk of ACS, highlighting the importance of optimizing cardiovascular risk factors in these patients.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Medicine, General & Internal
Heidi Kokkonen, Linda Johansson, Hans Stenlund, Solbritt Rantapaa-Dahlqvist
Summary: The increased comorbidity and mortality in rheumatoid arthritis (RA) patients are largely due to cardiovascular disease (CVD). Risk factors for CVD present in pre-RA individuals were associated with future cardiovascular events, and even after adjustments for these risk factors and treatments after RA onset, pre-RA individuals had a higher risk of cardiovascular events compared with controls.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
Ruth E. Costello, Belay B. Yimer, Polly Roads, Meghna Jani, William G. Dixon
Summary: The study found an association between the use of glucocorticoids and incident hypertension in patients with rheumatoid arthritis, especially at doses >= 7.5 mg. Clinicians should consider cardiovascular risk when prescribing glucocorticoids, and ensure regular monitoring and treatment of blood pressure.
Article
Multidisciplinary Sciences
Theis Christian Tonnessen, Arne Olav Melleby, Ida Marie Hauge-Iversen, Emil Knut Stenersen Espe, Mohammed Shakil Ahmed, Thor Ueland, Espen Andre Haavardsholm, Sara Marie Atkinson, Espen Melum, Havard Attramadal, Ivar Sjaastad, Leif Erik Vinge
Summary: Patients with rheumatoid arthritis have an increased risk of heart failure, but the experimental RA model in mice did not cause or modify HF caused by aortic constriction. This suggests that there are other prerequisites for RA-induced cardiac dysfunction.
Article
Rheumatology
Elena Myasoedova, John M. Davis, Veronique L. Roger, Sara J. Achenbach, Cynthia S. Crowson
Summary: Recent decades have shown a decline in major cardiovascular disease events in patients with rheumatoid arthritis, with the gap in occurrence between RA patients and the general population narrowing. Mortality after cardiovascular disease events in RA patients may be improving, with lower risk of death after incidents in the 1990s and 2000s compared to the 1980s.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jeneen Panezai, Ambereen Ghaffar, Mohammad Altamash, Mikael Aberg, Thomas E. Van Dyke, Anders Larsson, Per-Erik Engstrom
Summary: Periodontal disease enhances the expression of CVD-related biomarkers in RA patients through shared pathological clusters, concurrently enhancing metabolic and skeletal disease protein interactions, independent of autoimmune status.
Article
Rheumatology
Farzin Khosrow-Khavar, Seoyoung C. Kim, Hemin Lee, Su Been Lee, Rishi J. Desai
Summary: The study did not find evidence of increased cardiovascular risk with tofacitinib in patients with RA in a real-world setting. However, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Pharmacology & Pharmacy
Karel Hloch, Martin Dosedel, Jurjen Duintjer Tebbens, Lenka Zaloudkova, Helena Medkova, Jiri Vlcek, Tomas Soukup, Petr Pavek
Summary: Patients with rheumatoid arthritis who discontinue methotrexate treatment are at a significantly higher risk of cardiovascular diseases and all-cause mortality, highlighting the importance of stricter cardiovascular disease control in cases of methotrexate discontinuation.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Rheumatology
Maria Chiara Maccarone, Daniele Coraci, Gianluca Regazzo, Nicola Sarandria, Anna Scanu, Stefano Masiero
Summary: Long COVID syndrome refers to the new, returning, or persistent symptoms after the initial SARS-CoV-2 infection. Musculoskeletal symptoms have a significant impact on the quality of life in many patients. A literature review was conducted to explore the evolution of musculoskeletal symptoms in Long COVID syndrome. The findings highlight the need for interdisciplinary management and timely rehabilitative interventions.
Review
Rheumatology
Alexis Mathian, Renaud Felten, Marta E. Alarcon-Riquelme, Antony Psarras, Philippe Mertz, Francois Chasset, Edward M. Vital, Laurent Arnaud
Summary: Improved understanding of the molecular basis of innate immunity has led to the recognition of type I interferons (IFNs) as key mediators in the development of immunemediated inflammatory diseases (IMIDs). Pharmacological targeting of IFNs and their downstream signaling pathways, such as JAK1 and Tyk2, holds promise for the treatment of IMIDs.
Review
Rheumatology
Marie Robert, Marc Scherlinger
Summary: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune dysregulation and organ injury, involving the active role of platelets in the pathogenesis and disease progression. Platelets in SLE patients show intrinsic differences and can perpetuate inflammation by interacting with immune cells, thereby participating in organ damage and heightened cardiovascular mortality.
Review
Rheumatology
Jean Sibilia, Fabrice Berna, Jean-Gerard Bloch, Marc Scherlinger
Summary: Mind-body practices, such as mindfulness meditation, yoga, and Tai Chi, show promise in improving patient-reported outcomes in chronic rheumatic diseases, but their impact on inflammation and structural progression remains unclear.
Review
Rheumatology
Anne Tournadre, Marine Beauger
Summary: Obesity alters the characteristics of adipose tissue, leading to chronic low-grade inflammation, increased risk of chronic inflammatory diseases, and impact on treatment efficacy. Dietary and weight adjustments have a positive effect on improving inflammatory rheumatic diseases.
Article
Rheumatology
Romain Fore, Eric Liozon, Stephanie Dumonteil, Thomas Sene, Emmanuel Heron, Valentin Lacombe, Mathilde Leclercq, Julie Magnant, Clement Beuvon, Alexis Regent, Donatienne de Mornac, Maxime Samson, Perrine Smets, Jean-Francois Alexandra, Brigitte Granel, Pierre-Yves Robert, Muhammad Faiz Curumthaullee, Simon Parreau, Sylvain Palat, Holy Bezanahary, Kim Heang Ly, Anne-Laure Fauchais, Guillaume Gondran
Summary: This study aimed to evaluate whether the use of intravenous pulse of methylprednisolone reduces the risk of bilateral visual ischemia in patients with giant cell arteritis. The results showed no significant difference in the incidence of bilateral visual ischemia between the group receiving intravenous pulse of methylprednisolone and the group receiving direct prednisone.
Review
Rheumatology
Florent Eymard, Judith Aron-Wisnewsky
Summary: Obesity is a major modifiable risk factor for osteoarthritis (OA) and is associated with poorer outcomes in terms of pain, functional limitations, and response to treatments. Bariatric surgery (BS) can significantly reduce symptoms and improve function in patients with symptomatic knee OA, but its impact on long-term complications of arthroplasties appears to be disappointing. Overall, BS shows promise in reducing OA symptoms and potentially slowing disease progression.
Review
Rheumatology
Georges Marouna, Christina Fissouna, Marina Villaverde, Jean-Marc Brondelloa, Yves-Marie Pers
Summary: Recent discoveries have shown that the presence of senescent cells in osteoarticular tissues plays a crucial role in the development of osteoarthritis (OA). However, the senescence-regulatory factors associated with OA still need to be identified. Additionally, there is a lack of diagnostic and prognostic biomarkers currently used in clinics to evaluate OA patients. In the future, detecting senescence-regulatory biomarkers in patient fluids, along with imaging and clinical examination, could become a promising method for diagnosing, monitoring, assessing progression, and predicting prognosis in OA patients.
Article
Rheumatology
Patrick Yousif, Vicky Nahra, Muhammad A. Khan, Marina Magrey
Summary: Axial psoriatic arthritis (axPsA) has unique clinical and radiographic features compared to axial spondyloarthritis (axSpA). IL-23 inhibitors may be effective in treating axPsA, but further clinical trials are needed. Developing classification criteria and assessment tools for axPsA is also necessary.
Review
Rheumatology
Baptiste Gerard, Florian Bailly, Anne-Priscille Trouvin
Summary: This review aims to critically evaluate the effectiveness and safety of pharmacological treatments for chronic pain in rheumatic diseases, providing guidance for clinicians in selecting appropriate treatment options. The recommended pharmacological treatments vary depending on the specific rheumatic disease.